Waters Corporation Achieves Critical Milestone in Merger Process
Recently, Waters Corporation (NYSE: WAT) announced that during a critical meeting, its shareholders overwhelmingly supported a pivotal merger with Becton, Dickinson and Company (NYSE: BDX). This meeting marks a significant step in the ongoing integration of BD's Biosciences and Diagnostic Solutions division into Waters.
Overview of the Special Meeting
At the Special Meeting held by Waters, approximately 99% of participants voted in favor of the proposed transaction. The favorable decision signals strong confidence among shareholders in the merger's potential to propel Waters into a new era of growth and innovation.
Management's Response to Shareholder Support
Udit Batra, Ph.D., who serves as the President and Chief Executive Officer of Waters Corporation expressed gratitude towards shareholders, highlighting that this approval brings the company closer to finalizing the merger. Dr. Batra stated, "The support we received demonstrates the confidence in our strategy and our goal to enhance value for all associated parties, including patients, customers, employees, and investors." This sentiment underscores the company's commitment to fostering innovation within the life sciences and diagnostics sectors.
Details Surrounding the Merger
The merger is expected to officially close on February 9, 2026, following the completion of required regulatory conditions. Waters and BD have successfully navigated all necessary approvals, setting the stage for a seamless transition. The decision also benefits from a positive Private Letter Ruling from the Internal Revenue Service, regarding the tax framework for this transaction.
Future Financial Expectations
With the merger approaching its close, Waters has scheduled a financial results conference call for Q4 2025 on the same day. This call will highlight the company's performance and outlook, laying the groundwork for discussions about the merger impact. Interested parties can access the live webcast through Waters’ Investor Relations platform, with replays available for further review.
About Waters Corporation
Waters Corporation, established over 65 years ago, is recognized as a leader in analytical instruments, separations technologies, and software solutions. The company plays an essential role in ensuring safety and quality across life sciences, materials, food safety, and environmental sectors. With a dedicated workforce of over 7,600 employees operating in more than 100 countries, Waters focuses on delivering cutting-edge technology designed to improve the efficacy of medicines and the safety of consumables.
Frequently Asked Questions
What is the main outcome of the recent Special Meeting?
The shareholders voted unanimously in favor of the merger with BD's Biosciences and Diagnostic Solutions business.
When is the merger expected to close?
The merger is anticipated to finalize on February 9, 2026.
How will this merger benefit Waters Corporation?
The merger is expected to enhance Waters' market position and drive innovation in life sciences and diagnostics.
What is Waters Corporation known for?
Waters Corporation specializes in analytical instruments and solutions that ensure quality and safety across various industries.
Where can I find more information about Waters Corporation's financial results?
Financial results and updates will be available on Waters’ Investor Relations website, where a live webcast and replay will be accessible.
